LDH nano composite material of anti-FAP nano antibody as well as preparation method and application of LDH nano composite material

By loading anti-FAP nanocomposites on the surface of LDH, skin aging problems caused by ultraviolet radiation are solved, especially FAP overexpression and type I collagen degradation, achieving effective skin aging delay and ultraviolet shielding effects.

CN118903406APending Publication Date: 2024-11-08GUANGXI MEDICAL UNIVERSITY
View PDF 0 Cites 4 Cited by

Patent Information

Application Number
CN202310503190.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has not effectively solved the problem of skin aging caused by ultraviolet radiation, especially the role of FAP overexpression and type I collagen degradation in skin aging, but has not yet been targeted for treatment.

Method used

Develop an LDH nanocomposite material with anti-FAP nanoantibodies, which can block FAP overexpression and bind to the UV shielding performance of LDH by loading anti-FAP nanoantibodies on the LDH surface, and use its highly specific binding to FAP antigens to block FAP overexpression and bind to the ultraviolet shielding performance of LDH to delay Skin aging.

Benefits of technology

Effectively block the hydrolysis effect of FAP on type I collagen, prolong the half-life of the antibody, significantly reduce skin aging, achieve ultraviolet shielding effect, and delay the skin aging process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903406A_ABST
    Figure CN118903406A_ABST
Patent Text Reader

Abstract

The invention relates to an LDH nano composite material of an anti-FAP nano antibody and a preparation method and application thereof.The LDH nano composite material is prepared by taking LDH as a carrier through a surface adsorption means, and the preparation method comprises the steps that firstly, an expression system of FAP Nb is constructed, the nano antibody is prepared through in-vitro induction and multiplication culture, and then the nano antibody is obtained; the FAP Nb / LDH nano-composite biological material is constructed by a co-precipitation mode, the prepared FAP Nb / LDH nano-composite biological material has relatively stable physicochemical properties and also has a good ultraviolet ray radiation resistance effect, and the FAP Nb / LDH nano-composite biological material can improve the activity of superoxide dismutase in senescent normal human skin fibroblasts, and can improve the activity of superoxide dismutase in senescent normal human skin fibroblasts. Compared with the prior art, the application has the advantages that the activity of malondialdehyde is reduced, the expression of senescence markers P16, P21 and P53mRNA is reduced, and inflammatory factors IL-1beta, IL-2, IL-10 and TNF-alpha are remarkably reduced, so that the skin photoaging is effectively inhibited, an experimental basis is provided for clinical skin senescence resisting treatment, and a new clinical treatment strategy is provided for skin senescence prevention.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biocomposite materials, and in particular relates to an LDH nanocomposite material of an anti-FAP nanoantibody and a preparation method and application thereof. Background Art

[0002] Skin aging is affected by many factors, including genetic, physiological and environmental factors. Among them, ultraviolet rays (UV) radiation is one of the most important factors causing skin aging. Long-term exposure to ultraviolet rays, especially direct exposure to short-wavelength UVA and UVB, can damage the structural integrity of the skin and its normal physiological functions. This damage is collectively referred to as "skin photoaging", and its typical characteristics are the appearance of brown spots, dry skin, irregular pigmentation, and reduced skin elasticity to form wrinkles. UVB can pass through the epidermis and penetrate the upper dermis due to its high energy and short wavelength, which is the main cause of skin photoaging.

[0003] UVB radiation can not only directly damage biological macromolecules, such as deoxyribonucleotides, lipids and proteins, but also reduce the activity of antioxidant enzymes, such as superoxide dismutase and glutathione peroxidase, thereby increasing the production of reactive oxygen species (ROS) in the skin. On the one hand, the production of ROS induced by UVB promotes the activation of the transcription factor NF-κB pathway, which further stimulates the production of inflammatory cytokines, such as IL-1β, IL-6 and TNF-α; on the other hand, UVB radiation and UVB-induced ROS stimulate the production of cyclooxygenase-2 (COX-2), thereby upregulating the production of inflammatory mediators, such as inducible nitric oxide synthase (iNOS). These inflammatory mediators and cytokines will further accelerate the accumulation of ROS and enhance the expression of various matrix metalloproteinases (MMP) and fibroblast activation protein (FAP), accelerating the skin aging process. In particular, the overexpression of FAP triggers the degradation of type I collagen in skin tissue.

[0004] At present, drugs targeting FAP mainly include anti-FAP monoclonal antibodies, FAP molecular antagonists, etc. Most studies and reports focus on the use of anti-FAP antibodies to treat tumors and arthritis. However, in terms of anti-skin aging, there are no reports on drug research targeting FAP and regulating its expression level. Therefore, the research and development of anti-FAP pharmaceutical products has broad development prospects and industrial value for the treatment of skin aging.

[0005] Layered double hydroxides (LDHs) are a new type of inorganic nanomaterial. Due to its unique layered structure, positively charged surface, intercalation and adsorption capabilities, it can be hybridized with a variety of organic substances to exert its drug controlled release function. It has been widely used in drug delivery and bioimaging, showing great potential. At the same time, LDH is a widely used inorganic UV absorber with strong UV shielding properties. Due to its good biocompatibility, high water retention efficiency, low cost and other advantages, LDH has attracted widespread attention in the fields of UV protection and skin care.

[0006] The new composite material based on nanobody (Nanobody, Nb) and LDH will utilize the highly specific binding property of FAPNb loaded on the surface of LDH and FAP antigen to block the overexpression of FAP on the surface of fibroblasts in aged skin, reduce or eliminate its hydrolysis of type I collagen, utilize the protective effect of LDH on FAP Nb, extend the half-life of FAP Nb, and exert the ultraviolet shielding performance of LDH, in order to achieve the effect of delaying aging. Summary of the invention

[0007] The purpose of the present invention is to provide an engineered anti-FAP nanobody LDH nanocomposite material and its preparation method and application. The anti-FAP nanobody LDH nanocomposite material of the present invention has the following effects: blocking the overexpression of FAP on the surface of fibroblasts of aging skin, reducing or eliminating its hydrolysis of type I collagen, exerting the ultraviolet shielding performance of LDH, and achieving the effect of delaying skin aging.

[0008] To achieve the above object, the present invention adopts the following technical solutions:

[0009] According to a first aspect of the present invention, there is provided an anti-FAP nanobody and LDH nanocomposite material (FAP Nb / LDH), wherein the nanocomposite material comprises an anti-FAP nanobody and LDH, wherein the anti-FAP nanobody has the amino acid sequence shown in SEQ ID NO: 1, and the LDH is magnesium aluminum LDH (MgAl-LDH).

[0010] Wherein, the anti-FAP nanobody is a nanobody targeting the FAP epitope (FAP Nb).

[0011] Wherein, the anti-FAP nanobody is loaded on the surface of the LDH.

[0012] According to a second aspect of the present invention, a method for preparing an anti-FAP nanobody-LDH nanocomposite material is provided, the preparation method comprising: preparing an anti-FAP nanobody, and loading the anti-FAP nanobody on the surface of LDH to obtain the anti-FAP nanobody-LDH nanocomposite material, the anti-FAP nanobody having the amino acid sequence shown in SEQ ID NO: 1, and the LDH is magnesium-aluminum LDH.

[0013] Wherein, the DNA molecule encoding the anti-FAP nanobody has the nucleotide sequence shown in SEQ ID NO:2.

[0014] Among them, the preparation of anti-FAP nanoantibodies includes constructing an expression system for anti-FAP nanoantibodies and obtaining the anti-FAP nanoantibodies by in vitro induction and amplification culture.

[0015] Wherein, the anti-FAP nanobody is loaded on the surface of LDH by co-precipitation.

[0016] Among them, the anti-FAP nanoantibody is loaded on the LDH surface through electrostatic adsorption.

[0017] The preparation method further comprises the following steps:

[0018] (1) taking a MgCl2 aqueous solution, an AlCl3 aqueous solution and deionized water respectively and mixing them thoroughly to obtain a mixed solution;

[0019] (2) adding the mixed solution dropwise into the NaOH aqueous solution under stirring, and continuing stirring to obtain a suspension;

[0020] (3) taking the suspension and centrifuging it, discarding the supernatant, resuspending the precipitate with water, washing it, and resuspending it with water again to obtain a MgAl-LDH nanoparticle suspension for later use;

[0021] (4) Preparation of FAP recombinant plasmid;

[0022] (5) The FAP recombinant plasmid was transformed into Escherichia coli BL21, and the plasmid was transformed into BL21 DE3 competent cells by heat shock method, and IPTG was induced to produce a large amount of prokaryotic expressed FAP Nb, and the FAP Nb was purified to prepare a FAP Nb aqueous solution;

[0023] (6) Adding the MgAl-LDH nanoparticle suspension dropwise into the FAP Nb aqueous solution and stirring thoroughly to obtain a FAP Nb / LDH nanocomposite material.

[0024] Preferably, the preparation method further comprises:

[0025] Take MgCl2 aqueous solution, AlCl3 aqueous solution and deionized water respectively and mix them thoroughly to obtain a mixed solution. Take NaOH aqueous solution at room temperature and continue to stir, add the above mixed solution dropwise, continue to stir, and obtain a suspension. Take the suspension and centrifuge it, discard the supernatant, resuspend the precipitate with water, and wash it. According to this step, recycle and wash 2-3 times to obtain the prepared MgAl-LDH nanoparticle suspension.

[0026] Wherein, the concentration of the MgCl2 aqueous solution is 0.2-1.2 mol / L, preferably 0.6 mol / L, and the dosage is 2-10 mL, preferably 5 mL.

[0027] Wherein, the concentration of AlCl3 is 0.2-1.2 mol / L, preferably 0.6 mol / L, and the dosage is 0.5-3 mL, preferably 1.7 mL.

[0028] Wherein, the amount of deionized water used is 1.2-6 mL, preferably 3.3 mL.

[0029] The concentration of the NaOH aqueous solution is 0.05-0.45 mol / L, preferably 0.15 mol / L, and the dosage is 20-60 mL, preferably 40 mL. The rotation speed of the NaOH aqueous solution during continuous stirring is preferably 1000 rpm.

[0030] The mixed solution is pipetted with a pipette and added dropwise, and stirring is continued for 4-8 hours, preferably 6 hours.

[0031] The suspension was centrifuged at 5000 g for 5 minutes, the supernatant was discarded, and the precipitate was resuspended in 40 mL of ultrapure water for washing. The washing was repeated 2-3 times according to the steps. 2+ 、Al 3+ After the salt ions are fully washed away, the precipitate is resuspended in 40 mL of ultrapure water.

[0032] The MgAl-LDH nanoparticle suspension was added dropwise to the prepared FAP Nb aqueous solution, and stirred sufficiently at room temperature, wherein magnetic stirring was preferably performed at a speed of 1000 rpm for 0.5 h to prepare a FAP Nb / LDH nanocomposite material. The FAP Nb / LDH nanocomposite material was placed in a 50 mL centrifuge tube and stored at 4° C. for later use.

[0033] Wherein, the step of preparing the FAP recombinant plasmid further comprises:

[0034] a. Amplify the target gene FAP fragment by PCR: select appropriate homologous sequences to design primers, perform PCR amplification of the target gene, and purify the PCR product;

[0035] b. Enzyme digestion: digest the PCR product and FAP plasmid vector separately, and recover the digested products;

[0036] c. Ligation: The PCR product after restriction digestion and the plasmid vector are connected by ligase to obtain the FAP recombinant plasmid.

[0037] Preferably, the step of preparing an aqueous solution of FAP nanobodies comprises: using BeyoGold TM The His-tag purification kit was used to purify the bacterial supernatant after lysis to obtain the crude extract of FAP nanobody. After the crude extract was purified by ultrafiltration, its protein concentration was detected using a protein quantification kit, and different amounts of dd H2O were added to adjust it to various concentrations of FAP Nb aqueous solutions.

[0038] The MgAl-LDH nanoparticle suspension was added dropwise to the FAP Nb aqueous solution with different initial concentrations, and the mass ratio of LDH:FAP Nb was finally 8:1, 8:2, 8:4, 8:6, 8:8, and 8:10, respectively. The mixture was stirred at room temperature to obtain an LDH nanocomposite material of an anti-FAP nanobody.

[0039] According to the third aspect of the present invention, a pharmaceutical composition is provided, comprising the anti-FAP nanobody-LDH nanocomposite material and a pharmaceutically acceptable carrier.

[0040] According to a fourth aspect of the present invention, there is provided an application of an anti-FAP nanobody LDH nanocomposite material in the preparation of a preparation for delaying skin aging. Preferably, there is provided an application of an anti-FAP nanobody LDH nanocomposite material in the preparation of a preparation for treating skin aging caused by UVB radiation.

[0041] Physicochemical properties of LDH nanocomposites tested for anti-FAP nanobodies

[0042] The BCA method was used to detect the drug loading rate and adsorption rate of LDH on FAP Nb. The basic morphology and basic properties such as particle size, potential, and dispersion coefficient of FAP Nb / LDH nanocomposites were characterized by transmission electron microscopy and Malvern particle size analyzer. The crystal structure of FAP Nb / LDH nanocomposites was characterized by X-ray diffraction. The UV blocking performance of FAP Nb / LDH nanocomposites was detected by UV-visible spectroscopy.

[0043] In vitro toxicity test

[0044] Complete culture media containing 0.4 mg / L LDH, 0.3 mg / L FAP Nb and 0.7 mg / L FAP Nb / LDH nanocomposite material were prepared using DMEM complete culture medium. The relative proliferation rate of the cells was observed after co-culturing each group of culture media and DMEM complete culture medium (negative control group) and 0.64% phenol solution (positive control group) with HEK 293T human embryonic kidney cells and NIH 3T3 mouse embryonic fibroblasts for 24, 48, and 72 hours. The results are shown in the table below.

[0045] Table 1 RGR values ​​and cytotoxicity grades of each group at different time points

[0046]

[0047] In vitro aging model experiments

[0048] The aging model of normal human skin fibroblasts (NHDF cells) was established in vitro. nHDF cells were cultured at 3×10 5 Density was inoculated into 6-well plates. After 24 hours of normal culture, different concentrations of D-galactose (0g / L, 5g / L, 10g / L, 20g / L, 40g / L) were added to induce cells for 24 hours, 48 ​​hours, and 72 hours, respectively. A 6-well plate was selected for each concentration, of which 3 wells were cultured normally as the control group, and the other 3 wells were the experimental group with D-galactose added. The cell culture medium in the 6-well plate was aspirated at 24 hours, 48 ​​hours, and 72 hours, respectively, and washed once with 1×PBS, 1mL of β-galactosidase staining fixative was added, and the cell fixative was aspirated after fixation at room temperature for 15 minutes, and the cells were washed 3 times with PBS, each time for about 3 minutes. PBS was aspirated, 1mL of staining working solution was added to each well, and the cells were placed in a 37℃ carbon dioxide-free incubator for overnight incubation, and the 6-well plate was sealed with plastic wrap to prevent evaporation. The 6-well plate was taken out on the second day and counted under an ordinary optical microscope.

[0049] Use trypsin to digest nHDF cells in the logarithmic growth phase, centrifuge at 1000rpm for 5min, discard the supernatant, gently blow the cells again to mix them, and count the cells. Adjust the cell concentration according to the experimental needs, take 100μL each and add it to a 96-well plate. Place it in a 37℃ 5% CO2 incubator and culture it for 3-4 hours. After the cells adhere to the wall, carefully remove the culture medium in the 96-well plate, add 100μL of culture medium containing different concentrations of D-galactose (0g / L, 5g / L, 10g / L, 20g / L, 40g / L), and induce the cells for 24h, 48h, and 72h respectively. When the induction time is over, carefully remove the culture medium, wash once with 1×PBS, add 180μL of normal DMEM complete culture medium and 20μL of 0.5% MTT solution to each well, and continue to culture in the incubator for 4 hours. Remove the culture mixture, add 150 μL DMSO (dimethyl sulfoxide) solution to each well, and place on an oscillator to oscillate at an appropriate speed for 10 minutes. After the oscillation is completed, measure the A490 absorbance on a microplate reader. The positive rate of β-galactosidase staining is used as an indicator for identifying the degree of aging. When cultured at a concentration of 10 g / L for 48 hours, cell viability was not affected, and the positive rate of β-galactosidase staining increased. Therefore, 10 g / L D-galactose treatment for 48 hours was selected as the nHDF cell aging modeling condition.

[0050] The expression of FAP before and after modeling was detected by flow cytometry. The nHDF cells were revived and divided into a normal group (10% FBS DMEM complete medium) and a modeling group (D-galactose 10 g / LDMEM complete medium cultured for 48 h), digested and collected, counted, washed 3 times with PBS, and 1×10 6 The cells were placed in a flow cytometer, 5 μL of anti-FAP fluorescent flow cytometric monoclonal antibody was added, incubated at 4°C for 30 min, washed twice with PBS, centrifuged at 1000 rpm / min for 5 min, the supernatant was discarded, and the cells were resuspended with 500 μL of PBS. The samples were tested on a flow cytometer. The results were as follows: Figure 4 shown.

[0051] In vivo aging model experiments

[0052] A mouse skin aging model was constructed and randomly divided into Con, Mod, FAP Nb 0.6mg / kg, LDH 0.8mg / kg, FAPNb / LDH 0.35mg / kg, FAP Nb / LDH 0.7mg / kg, FAP Nb / LDH 1.4mg / kg and FAP Blockade groups. At the beginning of the experiment, except for the Con group, the other groups were subcutaneously injected with 5% D-galactose 10ml / kg on the back of the neck every day. Before injection, the drugs in each group were applied to the skin of the back of the neck of the mice, and the model was continuously established for 6 weeks. The water content of the mouse skin was detected to determine the anti-aging effect of FAP Nb / LDH nanocomposites on the skin in vivo. The ELISA method was used to detect the levels of glutathione peroxidase (GSH-PX), catalase (CAT), hydroxyproline (HYP) and cytokines IL-1β, IL-2, IL-10 and TNF-α in the skin tissue of each group of mice.

[0053] Skin tissue was taken for paraffin sections, and the histopathological changes of the skin were observed by HE staining and MASSON staining. The expressions of Col-I and MMP-1 in skin tissue were detected by immunohistochemical staining, and the mechanism of anti-skin aging of FAP Nb / LDH nanocomposites in vivo was analyzed.

[0054] The researchers of the present invention found that the FAP Nb / LDH nanocomposite material based on the novel composite material of nanoantibodies and LDH will utilize the highly specific binding property of FAP Nb loaded on the surface of LDH to the FAP antigen, block the overexpression of FAP on the surface of fibroblasts of aging skin, reduce or eliminate its hydrolysis of type I collagen, utilize the protective effect of LDH on FAP Nb, extend the half-life of FAP Nb, and simultaneously exert the ultraviolet shielding performance of LDH, in order to achieve the effect of delaying aging. This subject also further explores the relevant mechanisms of the protective effect of FAP Nb / LDH nanomaterials on type I collagen in vivo and in vitro through in vivo and in vitro experiments. The development of this novel nanoantibody-LDH nanocomposite material will provide a new strategy for the clinical prevention and treatment of skin aging. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 Schematic diagram of the structure of FAP Nb / LDH.

[0056] Figure 2 The morphological distribution of LDH and FAP Nb / LDH is shown.

[0057] Figure 3 Shown is the UV-visible absorption spectrum of FAP Nb / LDH.

[0058] Figure 4Shows the expression ratio of FAP before and after nHDF cell modeling.

[0059] Figure 5 Shows the comparison of GSH-PX, HYP, and CAT contents in the skin tissues of mice in each group.

[0060] Figure 6 Shows the comparison of IL-1β, IL-2, IL-10 and TNF-α levels in the skin tissue of mice in each group.

[0061] Figure 7 The results of skin tissue pathology of mice in each group are shown, with HE staining for group A and MASSON staining for group B.

[0062] Figure 8 The protein expression levels of human skin fibroblast senescence-related proteins Col-I and MMP-1 in the skin tissues of each group of mice are shown, with Group A showing Col-I and Group B showing MMP-1. DETAILED DESCRIPTION

[0063] The present invention is further described in detail below in conjunction with specific embodiments. The given examples are only for illustrating the present invention, but not for limiting the scope of the present invention.

[0064] The experimental methods in the following examples are all conventional methods unless otherwise specified.

[0065] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0066] Example 1 Preparation and characterization of FAP Nb / LDH nanomaterials

[0067] (1) Prokaryotic induction of FAP Nb expression

[0068] The FAP recombinant plasmid was transformed into Escherichia coli BL21 (DE3). The plasmid was transformed into BL21 (DE3) competent cells by heat shock method. The IPTG induction conditions (such as IPTG induction concentration, induction time and temperature) were optimized, and the optimal conditions were finally determined for large-scale prokaryotic expression of FAP Nb. The optimal induction conditions of FAP Nb were: IPTG concentration of 0.1mM, temperature of 15℃, and induction time of 6h. The supernatant of the lysed bacteria was purified using the BeyoGoldTM His-tag purification kit to obtain the crude extract of FAP nanobody. After further purification of the crude extract by ultrafiltration, the protein concentration was detected using a protein quantification kit, and different amounts of dd H2O were added to adjust it to various concentrations of FAP Nb aqueous solution.

[0069] (2) Synthesis of FAP Nb / LDH by coprecipitation method

[0070] Pipette 5mL of 0.6mol / L MgCl2 aqueous solution, 1.7mL of AlCl3 aqueous solution and 3.3mL of deionized water into a small beaker and mix thoroughly. Measure 40mL of 0.15mol / L NaOH aqueous solution into a conical flask and put it into a rotor. At room temperature and stirring at 1000rpm, use a pipette to pipette the Mg and Al mixed solution in the small beaker dropwise and add all of it. Continue magnetic stirring for 6 hours to obtain a suspension. Pipette the suspension into a centrifuge tube and centrifuge at 5000g for 5 minutes. After discarding the supernatant, resuspend the precipitate with 40mL of ultrapure water and centrifuge and wash it twice again. 2+ 、Al 3+ The salt ions were fully washed away, and the precipitate was resuspended in 40 mL of ultrapure water. The prepared MgAl-LDH nanoparticle suspension was added dropwise to the FAPNb aqueous solution with different initial concentrations, and the final LDH to FAP Nb mass ratio was 8:1, 8:2, 8:4, 8:6, 8:8, 8:10, respectively, and magnetic stirring was carried out at 1000 rpm for 0.5 h at room temperature. The prepared FAP Nb / LDH nanomaterial was placed in a 50 mL centrifuge tube and stored at 4 ° C for later use.

[0071] (3) Analysis of the physical and chemical properties of FAP Nb / LDH nanocomposites

[0072] Transmission electron microscopy, X-ray diffraction, UV-visible absorption spectroscopy, etc. were used to detect the physical and chemical properties of FAP Nb / LDH nanocomposites, such as drug loading rate, adsorption rate, particle size, potential and dispersion coefficient. Figure 2 The UV-visible absorption spectra of FAP Nb (0.3 mg / L), LDH (0.4 mg / L) and FAP Nb / LDH (0.7 mg / L) are shown in Figure 3 shown.

[0073] The results show that when the LDH:FAP Nb mass ratio is in the range of 8:1 to 8:10, as the mass of FAP Nb increases, the drug loading rate of LDH on FAP Nb gradually increases, reaching the maximum drug loading rate at 8:6, and the drug loading rate will no longer increase with the continued increase of the FAP Nb mass. When the LDH:FAP Nb mass ratio is 8:6, the average Zeta potential of the FAP Nb / LDH nanomaterial dispersion system is about -20mV. When the LDH:FAP Nb mass ratio is 8:6, the PDI (dispersion coefficient) value is 0.348 and the particle size is 132.3±5.2nm. The results show that FAP Nb / LDH nanomaterials have good stability, uniform material, good ultraviolet radiation blocking properties, and good cell compatibility.

[0074] Example 2 ELISA method was used to detect the content of GSH-PX, HYP and CAT in the skin tissue of each group of mice after treatment with FAP Nb / LDH nanocomposite materials

[0075] Take the skin from the back of the neck, wipe it dry with filter paper, weigh it accurately with a precision electronic balance, grind it, add pre-cooled NS culture medium, homogenize it, and take the supernatant. The groups are as follows: Con group, Mod group, FAP Nb 0.6mg / kg group, LDH 0.8mg / kg group, FAP Nb / LDH0.35mg / kg group, FAP Nb / LDH 0.7mg / kg group, FAP Nb / LDH 1.4mg / kg group and FAP Blockade. Prepare the standard products in the ELISA kit of GSH-PX, HYP, and CAT with concentration gradient, and add them to the 96-well plate that has been soaked with washing solution. After the sample diluent is diluted 1:4 times, take 100μL and add it to the 96-well plate that has been soaked. Add 50μL of the diluted corresponding detection antibody to each well. Seal the plate with a sealing film and incubate it at room temperature for 2h. Pour off the liquid in the 96-well plate, wash the 96-well plate with the prepared washing solution, pour off the liquid in the wells and pat dry the residual liquid in the wells on absorbent paper, repeat 6 times. Use an ELISA kit to detect the absorbance of each sample to determine the secretion level of GSH-PX, HYP, and CAT in each group. The results are as follows: Figure 5 shown.

[0076] From the results, it can be seen that the contents of GSH-PX, HYP and CAT increased at different levels, and the contents increased with the increase of the concentration of FAP Nb / LDH nanocomposite materials, thus achieving the effect of anti-skin photoaging.

[0077] Example 3 ELISA method was used to detect the contents of IL-1β, IL-2, IL-10 and TNF-α in the skin tissue of each group of mice after treatment with FAP Nb / LDH nanocomposite materials

[0078] Take the skin from the back of the neck, wipe it dry with filter paper, weigh it accurately with a precision electronic balance, grind it, add pre-cooled NS culture medium, homogenize it, and take the supernatant. The groups are as follows: Con group, Mod group, FAP Nb 0.6mg / kg group, LDH 0.8mg / kg group, FAP Nb / LDH0.35mg / kg group, FAP Nb / LDH 0.7mg / kg group, FAP Nb / LDH 1.4mg / kg group and FAP Blockade. Prepare the concentration gradient of IL-1β, IL-2, IL-10, and TNF-α standard products in the kit, and add them to the 96-well plate that has been soaked with washing solution. After the sample diluent is diluted 1:4 times, take 100μL and add it to the soaked 96-well plate. Add 50μL of the diluted corresponding detection antibody to each well. Seal the plate with a sealing film and incubate it at room temperature for 2h. Pour out the liquid in the 96-well plate, wash the 96-well plate with the prepared washing solution, pour out the liquid in the wells and pat dry the residual liquid in the wells on absorbent paper, repeat 6 times. Add 100μL of diluted horseradish peroxidase-labeled streptavidin to each well. Seal the plate with a new sealing membrane. Oscillate at 300rpm / min and incubate at room temperature for 45min. Pour out the liquid in the 96-well plate, wash the 96-well plate with the prepared washing solution, pour out the liquid in the wells and pat dry the residual liquid in the wells on absorbent paper, repeat 6 times. Add 100μL of the colorimetric substrate TMB to each well, protect from light, incubate at room temperature for 30min, and then detect. The results are as follows: Figure 6 shown.

[0079] Example 4 Observation of pathological changes in skin tissue of mice in each group by HE staining and MASSON staining

[0080] (1) Take fresh skin tissue and rinse it with PBS three times, 3 min each time, fix the tissue with 4% paraformaldehyde tissue fixative, put it in a glass bottle, and store it in a refrigerator at 4℃.

[0081] (2) Remove the tissue blocks, wash the tissue with water, and dehydrate it with 75%, 80%, 85%, 90%, 95%, and 100% graded alcohol in sequence, each time for 1 hour.

[0082] (3) After gradient alcohol dehydration, the tissue was cleared in a 1:1 ratio of alcohol (100%):xylene for 1 h, and then cleared in xylene I and xylene II for 15 min each.

[0083] (4) The dehydrated tissue was placed in a mixture of xylene and paraffin in a ratio of 1:1 and immersed in wax in a 55°C incubator for 40 min. It was then placed in paraffin I, paraffin II, and paraffin III in a 55°C incubator and immersed in wax for 60 min each.

[0084] (5) Turn on the paraffin embedding machine to preheat the paraffin, install the paraffin box and place it in the appropriate position, mark the wax-impregnated tissue and place it in the paraffin box, turn on the paraffin switch to inject paraffin into the paraffin box, quickly place the tissue block in the appropriate position at the bottom for embedding, take out the paraffin block, cool it, and store it in a refrigerator at 4°C.

[0085] (6) Take out the trimmed paraffin block, fix it on a paraffin slicer, adjust the scale and slice it to a thickness of 5 μm. Quickly use tweezers to place the slices in the water of the slice spreader and flatten them. Immediately pick them up with a cover slip and flatten them. Bake the slices in a 45°C incubator for 1 hour to dry them, and store them in a slide box.

[0086] HE staining: The sections were routinely dewaxed with xylene, washed with various levels of ethanol and water: xylene for 5 minutes, 100% ethanol for 2 minutes, 95% ethanol for 1 minute, 80% ethanol for 1 minute, 75% ethanol for 1 minute, and washed with distilled water. Hematoxylin staining for 5 minutes, rinsed with tap water. Hydrochloric acid ethanol differentiation for 30 seconds, soaked in tap water for 15 minutes or warm water (about 50°C) for 5 minutes, and placed in eosin solution for 2 minutes. Conventional dehydration, transparency, and sealing: 95% ethanol for 1 minute → 100% ethanol for 1 minute → xylene carbolic acid (3:1) for 1 minute → xylene I for 1 minute → xylene II for 1 minute → neutral resin sealing.

[0087] MASSON staining: The sections were routinely dewaxed and stained with Weigert iron hematoxylin stain for 5-10 minutes. Differentiated and washed with acidic ethanol differentiation solution. Then blued and washed with ammonia solution. Washed with distilled water or deionized water for 1 minute. Then stained with Ponceau fuchsin stain for 5-10 minutes. After completion, washed with acetic acid solution for 1 minute, phosphomolybdic acid solution for 1-2 minutes, and then washed with acetic acid solution for 1 minute. Directly placed in aniline blue stain for 1-2 minutes. Then washed with acetic acid solution for 1 minute. Rapidly dehydrated with 95% ethanol. Absolute ethanol for 5-10 seconds three times, xylene for 1-2 minutes three times, and sealed with neutral gum.

[0088] The results are as follows Figure 7 As shown in the results, it can be seen that FAP Nb / LDH can inhibit the reduction of collagen fibers and reduce the infiltration of inflammatory cells, thereby achieving the effect of inhibiting skin photoaging.

[0089] Example 5 Observation of the Expression of Col-I and MMP-1 in Mouse Skin Tissue by Immunohistochemistry

[0090] Immunohistochemistry is an experimental technique that uses antigen-antibody reaction to identify antigens in tissue cells and characterize protein localization by developing color with a color developer that labels the antibody. The specific steps are as follows:

[0091] Bake the slices in a 60℃ incubator for 30 minutes to dewax until the moisture is dry. Put the slices into xylene I for 10 minutes → xylene II for 10 minutes → 100% alcohol for 5 minutes → 95% alcohol for 5 minutes → 85% alcohol for 5 minutes → 80% alcohol for 5 minutes → 70% alcohol for 5 minutes → put them in a cup of tap water and wash them for 15 minutes.

[0092] Immerse the slices completely in citrate buffer (pH 6.0), heat the pressure cooker to boiling and then turn off the power. Repeat 1 to 2 times after 5 to 10 minutes of pressure interval. After cooling, wash with PBS (pH 7.2-7.6) 1 to 2 times, 5 minutes each time.

[0093] Block endogenous peroxidase: Drain PBS, circle the skin tissue area with an immunohistochemical oil pen, and add 100 μL of endogenous peroxidase blocker, incubate at room temperature for 10 minutes to reduce the activity of endogenous peroxidase. Wash with PBS 3 times, 3 minutes each time.

[0094] Serum blocking: Use serum from the same source as the secondary antibody to block some non-specific binding sites. Add 100 μL of animal non-immune serum to the tissue in the circle and leave it at room temperature for 10 minutes.

[0095] Incubate with primary antibody: remove serum, add 50 μL of primary antibody to the tissue in the circle, and incubate at 4°C overnight or at 37°C for 1-2 hours (generally, after overnight at 4°C, the slices need to be placed at 37°C for 45 minutes to prevent detachment and to make the antigen-antibody binding more stable).

[0096] Incubation with secondary antibody: Wash with PBS three times, 3 min / time, add 50 μL of biotin-labeled IgG to the tissue in the circle and leave at room temperature for 15 min.

[0097] Incubation with the third antibody: Wash with PBS three times, 3 min each time, add 50 μL of streptavidin-peroxidase to the tissue in the circle and leave at room temperature for 5 min.

[0098] Color development: Wash 3 times with PBS, 3 min / time, remove PBS solution, add 100 μL DAB color development solution (it is best to prepare the color development solution before use, add 50 μL of A, B, and C solution to 850 μL water), incubate for 5-10 min, observe whether the staining is obvious (brown) under a microscope, and rinse the slides with tap water to terminate color development.

[0099] In order to form the cell outline and better locate the target protein, add 100 μL of hematoxylin cell staining solution and incubate for 1 minute, rinse with tap water 3 times, 1 minute / time, separate with 1% hydrochloric acid alcohol for 20 seconds, and wash with tap water for 5 minutes to return to blue. After drying, seal the slide with neutral gum and observe the results under a microscope. Figure 8As shown, the results showed that FAP Nb / LDH nanomaterials can reduce the level of MMP-1 in the epidermis and promote the expression of Col-I by blocking the degradation of type I collagen by FAP, thereby effectively inhibiting skin photoaging.

[0100] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. An anti-FAP nanobody LDH nanocomposite material, characterized in that: The nanocomposite material comprises an anti-FAP nanobody and LDH, wherein the anti-FAP nanobody has an amino acid sequence shown in SEQ ID NO: 1, and the LDH is magnesium-aluminum LDH.

2. The nanocomposite material as claimed in claim 1, wherein the anti-FAP nanobody is loaded on the surface of the LDH.

3. A method for preparing an anti-FAP nanobody LDH nanocomposite material, the preparation method comprising: An anti-FAP nanobody is prepared, and the anti-FAP nanobody is loaded on the surface of LDH to obtain the anti-FAP nanobody-LDH nanocomposite material, wherein the anti-FAP nanobody has the amino acid sequence shown in SEQ ID NO: 1, and the LDH is magnesium-aluminum LDH.

4. The preparation method according to claim 3, wherein the preparation of the anti-FAP nanobody comprises constructing an expression system for the anti-FAP nanobody and obtaining the anti-FAP nanobody by in vitro induction and amplification culture.

5. The preparation method according to claim 3, comprising the steps of: (1) taking a MgCl2 aqueous solution, an AlCl3 aqueous solution and deionized water respectively and mixing them thoroughly to obtain a mixed solution; (2) adding the mixed solution dropwise into the NaOH aqueous solution under stirring, and continuing stirring to obtain a suspension; (3) taking the suspension and centrifuging it, discarding the supernatant, resuspending the precipitate with water, washing it, and resuspending it with water again to obtain a MgAl-LDH nanoparticle suspension for later use; (4) Preparation of FAP recombinant plasmid; (5) transforming the FAP recombinant plasmid into Escherichia coli BL21 to prepare FAP Nb, and purifying the FAP Nb to prepare a FAPNb aqueous solution; (6) Adding the MgAl-LDH nanoparticle suspension dropwise into the FAP Nb aqueous solution and stirring thoroughly to obtain a FAP Nb / LDH nanocomposite material.

6. The preparation method according to claim 5, wherein step (4) comprises: a. Amplify the target gene FAP fragment by PCR: select appropriate homologous sequences to design primers, perform PCR amplification of the target gene, and purify the PCR product; b. Enzyme digestion: digest the PCR product and FAP plasmid vector separately, and recover the digested products; c. Ligation: The PCR product after restriction digestion and the plasmid vector are connected by ligase to obtain the FAP recombinant plasmid.

7. The preparation method according to claim 5, wherein the concentration of the MgCl2 aqueous solution in step (1) is 0.2-1.2 mol / L, and the amount used is 2-10 mL; the concentration of the AlCl3 is 0.6 mol / L, and the amount used is 0.5-3 mL; and the amount of the deionized water is 1.2-6 mL.

8. The preparation method according to claim 5, wherein the concentration of the NaOH aqueous solution in step (2) is 0.05-0.45 mol / L and the amount used is 20-60 mL.

9. A pharmaceutical composition comprising the LDH nanocomposite material of the anti-FAP nanobody according to claim 1 or 2 and a pharmaceutically acceptable carrier.

10. Use of the anti-FAP nanobody and LDH nanocomposite material according to claim 1 or 2 in the preparation of a preparation for delaying skin aging.

Citation Information

Cited By

  • Preparation method and application of novel CAR T cell capable of secreting CTLA-4 nano antibody and targeting FAP

    CN116286656A

  • A novel method for preparing and applying CTLA-4 secreted nanobody-targeted FAP-based CAR T cells

    CN116286656B

  • LDH nano composite material loaded with CD105 nano antibody as well as preparation method and application of LDH nano composite material

    CN120815191A

  • LDH nanocomposites loaded with cd105 nanobodies, methods of making and uses thereof

    CN120815191B